IMNM News and Press, Immunome Inc. From 04/12/24

2024-04-12 14:12:23 ET Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activat...

2024-04-03 16:44:05 ET More on Immunome Immunome: An Oncology Powerhouse In The Making Immunome: Why It Has Doubled Over The Last Month Immunome down 1%, prices $200M equity Read the full article on Seeking Alpha For further details see: Immunome ...

2024-04-02 14:07:46 ET Summary IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25...

2024-04-01 09:00:06 ET David Nierengarten from Wedbush issued a price target of $33.00 for IMNM on 2024-04-01 07:59:00. The adjusted price target was set to $33.00. At the time of the announcement, IMNM was trading at $24.68. IMNM currently trades -20.38% versus its 52 w...

2024-03-28 17:07:10 ET More on Immunome Immunome: Why It Has Doubled Over The Last Month Immunome down 1%, prices $200M equity Immunome announces underwritten public offering of common stock Read the full article on Seeking Alpha For further details s...

Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on...

Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. “AL102 is a hi...